Gene ther­a­py biotech Cap­si­da lays off work­ers af­ter ex­pand­ing Ab­b­Vie pact, adding Lil­ly col­lab

Gene ther­a­py start­up Cap­si­da Bio­ther­a­peu­tics said it is lay­ing off em­ploy­ees, months af­ter un­veil­ing two Big Phar­ma part­ner­ships that brought in $125 mil­lion.

Cap­si­da CEO Pe­ter Anas­ta­siou de­clined to com­ment on the num­ber of em­ploy­ees im­pact­ed. At the end of May, Cap­si­da had 138 em­ploy­ees, per a tal­ly from da­ta firm Pitch­Book.

The Thou­sand Oaks, CA-based start­up fol­lows some of its gene ther­a­py peers and oth­er fledg­ling drug de­vel­op­ers by down­siz­ing in the past 18 months, with many cit­ing the state of fi­nanc­ing for the in­dus­try’s young batch of com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER